Kinase Inhibitors For Cancer Treatment Market

Kinase Inhibitors For Cancer Treatment Market Outlook

The global kinase inhibitors for cancer treatment market is expected to reach a valuation of US$ 122,133.64 million by 2032. The market is valued at US$ 45,000 million as of 2022 and is anticipated to grow at a CAGR of 10.5% during the forecast.

Presently, pharmaceutical companies are investing heavily in R&D to develop enhanced kinase inhibitors. This is currently driving the market growth.

Moreover, there are massive technological developments happening in the healthcare sector, especially in the area of cancer treatment. Companies are making use of this technology to develop much more evolved forms of tyrosine kinase inhibitors. This might increase the demand for kinase inhibitors for cancer treatment during the forecast period.

Additionally, the number of cancer patients has been increasing worldwide over the past few years. Based on the statistics provided by WCRF, as of 2020, there were 18.1 million cancer cases. Thus, an exponential increase in the number of cancer cases is expected to surge the sales of kinase inhibitors for cancer treatment worldwide.

The key players operating in the oncology market are particularly betting on the ease of oral administration and the ability to target multiple cellular survival pathways by the application of kinase inhibitors. Thus, oncologists are of the view that the application of tyrosine kinase inhibitors drugs is much more beneficial as compared to traditional therapies. This is expected to increase the kinase inhibitors for cancer treatment market share.

Kinase Inhibitors are specific enzymes which oppose the process of cell division and growth in cancerous cells. It comes handy in treatment of cancer by blocking the signals that notify a cell to divide and grow. In last few decades, there has been significant progress made in the development of cancer treatment such as chemotherapy.

However, these drugs used cancer treatment have a restricted therapeutic index, also the result are only unpredictable, partial, brief, palliative as well as uncertain. In contrast, kinase inhibitor therapy which has recently been introduced is specifically targeted towards cancer molecules and signaling pathways.

Such targets are normally found in tumor cells, resulting wider therapeutic index and minimum adverse effect.

Significant changes have been made in cancer treatment from last decade and kinase inhibitors therapy signifies to a latest generation of anticancer treatment that are intended to interfere with a particular molecular target, normally a protein with an important role in tumor development or growth.

This methodology differs from the more observed approach used in orthodox cytotoxic chemotherapy, which has continued to be the backbone of cancer treatment over past several years. Kinase inhibitors therapy has the possibility to eliminate or reduce many of the present difficulties in the area of cytotoxic chemotherapy, such as the causing serious host-cell toxicity.

What are the Factors limiting the Potential of the Market?

However, the high cost associated with the treatment might affect the market growth. Apart from that, the complex process pertaining to approvals from regulatory authorities might cause further inhibitions going ahead.

Moreover, the patient who undergoes kinase inhibitors for cancer treatment might experience certain side effects like nausea, vomiting, diarrhoea, fatigue, rashes, etc. This as well is expected to challenge the adoption of kinase inhibitors for cancer treatment during the forecast period.

On the basis of regional analysis, it was found that Europe had the largest market share. The growing geriatric population, coupled with major technological advancements in the healthcare sector, is currently driving the Europe market.

North America is expected to showcase massive development during the forecast period. The region currently has the largest healthcare market and is expected to grow by leaps and bounds.

However, if we talk about the fastest-growing market, it would be Asia-Pacific. Increased investment by the governments and various healthcare authorities in the region, coupled with an improving healthcare infrastructure, is expected to surge the kinase inhibitors for the cancer treatment market during the forecast period.

Based on the end user, the hospital segment is expected to have the highest market share during the forecast period. An increasing number of cancer patients getting admitted to hospitals happens to be the major reason why the segment is expected to have the highest market share.

In October 2022, researchers from the UVA Health Care Center developed an algorithm that will improve cancer care by quickly and efficiently identifying patients who will benefit from the application of kinase inhibitors.

Kinase Inhibitors for Cancer Treatment Market: Drivers and Restraints

Enhancedemphasis of pharmaceutical companies on R&D to come up with potential kinase inhibitors for treatment of cancers. Is driving the growth of kinase inhibitor treatment market, globally.

Presently,kinase inhibitors for cancer treatmentglobal market is driven by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease.

However, high cost associated with latest clinical trials and complex approvals processes are acting as a major obstructions for the growth of kinase inhibitors for cancer treatmentglobal market.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Kinase Inhibitors for Cancer Treatment Market: Overview

The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period. There are reasons for healthy growth rate in the forecast period such asfast technological development, upsurge in the number of incidence of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe

Kinase Inhibitors for Cancer Treatment Market: Region-wise Outlook

Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.

In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.

Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients. Thereby, contribute to the growth of global kinase inhibitors for cancer treatmentmarket value.

The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.

Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Sign-Up

Kinase Inhibitors for Cancer Treatment Market: Key Players

Some of the key participating global players in kinase inhibitors for cancer treatment global market are Pfizer Inc., Boehringer Ingelheim GmbH, Novartis AG, Incyte Corporation, MedImmune, AstraZeneca, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies.

The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
• Eastern Europe (Poland, Russia)
• Asia Pacific (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Kinase Inhibitors for Cancer Treatment Market: Segmentation

Kinase inhibitors for cancer treatment globalmarketis segmented into following types:

By Product Type:

• Angiogenesis inhibitors
• m-TOR inhibitors
• BRAF and MEK inhibitors
• Bcr-Abl tyrosine-kinase inhibitors (TKI)
• EGFR inhibitors
• Others (PI3K Inhibitors, aurora-kinase inhibitors etc)

End User:

• Hospitals
• Research Organizations

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• Japan
• MEA